Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

作者：Yuankai Shi, Lin Wu, Yinghua Ji, Gongyan Chen, Baolan Li, Minghong Bi, Runxiang Yang, Liyun Miao, Guo‐Jun Zhang, Hongjun Gao, Longhua Sun, Mingjun Zhang, Shundong Cang, Meili Sun, Wenxiu Yao, Zhijie Pan, Jiuwei Cui, Yi Xiao, Qiming Wang, Yongxiang Song, Meiqi Shi, Daqing Wang, Zeng Li, Hailong Liu, Xiaorong Dong, Xiang Wang, Jian Fang, Yanyan Xie, Aimin Zang, Mingwei Chen, Xia Song, Kun Wang, Bi Chen, Qun Chen, Huijuan Wang, Ping Sun, Wei Li, Yanming Zhang, Diansheng Zhong, Xuezhi Hao, Tong Zhou, Yuansong Bai, Jianhua Shi, Yu Zhang, Jun Li, Yajun Li, Jiawen Xiao, Hongming Pan, Yaning Zhao, Hong Lu, Mei Yin, Hongyu Chen, Tingting Song, Xuyu Wei · 发表于：The Lancet Respiratory Medicine · 年份：2025 · DOI：10.1016/s2213-2600(25)00121-3 · 被引用次数：14 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Diagnosis and Treatment